MRI-guided dynamic risk assessment in cervical cancer based on tumor hypoxia at diagnosis and volume response at brachytherapy

被引:0
|
作者
Skipar, Kjersti [1 ,2 ,3 ]
Hompland, Tord [1 ]
Lund, Kjersti V. [3 ]
Lindemann, Kristina [3 ,4 ]
Hellebust, Taran P. [5 ]
Bruheim, Kjersti [6 ]
Lyng, Heidi [1 ,7 ,8 ]
机构
[1] Oslo Univ Hosp, Dept Radiat Biol, Oslo, Norway
[2] Telemark Hosp Trust, Dept Oncol, Skien, Norway
[3] Univ Oslo, Inst Clin Med, Oslo, Norway
[4] Oslo Univ Hosp, Dept Gynecol Oncol, Oslo, Norway
[5] Oslo Univ Hosp, Dept Med Phys, Oslo, Norway
[6] Oslo Univ Hosp, Dept Oncol, Oslo, Norway
[7] Univ Oslo, Dept Phys, Oslo, Norway
[8] Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Radiat Biol, Ullernchausseen 70, N-0379 Oslo, Norway
关键词
CONCURRENT CHEMORADIOTHERAPY; ADAPTIVE BRACHYTHERAPY; WORKING GROUP; RADIOTHERAPY; IMMUNOTHERAPY; REGRESSION; SURVIVAL;
D O I
10.1016/j.radonc.2024.110263
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: Improvements in treatment outcome for patients with locally advanced cervical cancer (LACC) require a better classification of patients according to their risk of recurrence. We investigated whether an imaging -based approach, combining pretreatment hypoxia and tumor response during therapy, could improve risk classification. Material and methods: Ninety-three LACC patients with T2-weigthed (T2W)-, dynamic contrast enhanced (DCE)- and diffusion weighted (DW)-magnetic resonance (MR) images acquired before treatment, and T2W- and, for 64 patients, DW-MR images, acquired at brachytherapy, were collected. Pretreatment hypoxic fraction (HFpre) was determined from DCE- and DW-MR images using the consumption and supply -based hypoxia (CSH)-imaging method. Volume regression at brachytherapy was assessed from T2W-MR images and combined with HFpre. In 17 patients with adequate DW-MR images at brachytherapy, the apparent diffusion coefficient (ADC), reflecting tumor cell density, was calculated. Change in ADC during therapy was combined with volume regression yielding functional regression explorative response measure. Endpoint was disease free survival (DFS). Results: HFpre was the strongest predictor of DFS, but a significant correlation with outcome was found also for volume regression. The combination of HFpre and volume regression showed a stronger association with DFS than HFpre alone. Patients with disease recurrence were selected to either the intermediate- or high -risk group with a 100 % accuracy. Functional regression showed a stronger correlation to HFpre than volume regression. Conclusion: The combination of pretreatment hypoxia and volume regression at brachytherapy improved patient risk classification. Integration of ADC with volume regression showed promise as a new tumor response parameter.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] MRI-guided Brachytherapy for Cervical Cancer - Is Dynamic Contrast Enhanced MRI Useful?
    Yuh, W. C.
    Wang, J. Z.
    Huang, Z.
    Li, K.
    Sammet, S.
    Liang, J.
    Lu, L.
    Knopp, M. V.
    Mayr, N. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S123 - S123
  • [2] Outcome Assessment of Dose Adaptation of MRI-Guided Cervical Cancer Brachytherapy
    Venkat, P. S.
    Altazi, B.
    Biagioli, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S491 - S491
  • [3] Metal artefacts in MRI-guided brachytherapy of cervical cancer
    Soliman, Abraam S.
    Owrangi, Amir
    Ravi, Ananth
    Song, William Y.
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2016, 8 (04) : 363 - 369
  • [4] Automatic Tandem and Ring Digitization for MRI-Guided Cervical Cancer Brachytherapy
    Hrinivich, W. T.
    Morcos, M.
    Lee, J.
    Viswanathan, A.
    McNutt, T.
    MEDICAL PHYSICS, 2018, 45 (06) : E140 - E140
  • [5] Dose and Volume Response for Local Control in Locally Advanced Cervical Cancer Treated With EBRT Combined With MRI-Guided Adaptive Brachytherapy
    Tanderup, K.
    Fokdal, L. U.
    Sturdza, A. E.
    Mazeron, R.
    Kirisits, C.
    Lindegaard, J. C.
    Doerr, W.
    Poetter, R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S91 - S92
  • [6] MRI ASSESSMENT OF TUMOUR SPREAD AND RESPONSE FOR IMAGE GUIDED CERVICAL CANCER BRACHYTHERAPY
    Dimopoulos, J.
    Bauer, V.
    Petrie, P.
    Berger, D.
    Kirisits, C.
    Woehs, V.
    Fidarova, E.
    Lang, S.
    Poetter, R.
    RADIOTHERAPY AND ONCOLOGY, 2008, 88 : S90 - S90
  • [7] Clinical outcomes with MRI-guided image-based brachytherapy in cervical cancer: An institutional experience
    Simha, Vijai
    Rai, Bhavana
    Patel, Firuza D.
    Kapoor, Rakesh
    Sharma, Suresh C.
    Singh, Oinam A.
    Singla, Veenu
    Dhanireddy, Bhaswanth
    Ghoshal, Sushmita
    BRACHYTHERAPY, 2018, 17 (02) : 345 - 351
  • [8] Comparison of spinal and general anesthesia approaches for MRI-guided brachytherapy for cervical cancer
    Frankart, Andrew J.
    Meier, Teresa
    Minges, Thomas L.
    Kharofa, Jordan
    BRACHYTHERAPY, 2018, 17 (05) : 761 - 767
  • [9] Dose and Volume Parameters for MRI-Guided Cervix Cancer Brachytherapy in the Embrace Trial
    Nesvacil, N.
    Potter, R.
    Tanderup, K.
    Dumas, I.
    Swamidas, J.
    De Leeuw, A.
    Hudej, R.
    Lowe, G.
    Spampinato, S.
    Lindegaard, J.
    Jurgenliemk-Schulz, I.
    Kirisits, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : S220 - S220
  • [10] Practically achievable maximum high-risk clinical target volume doses in MRI-guided intracavitary brachytherapy for cervical cancer: A planning study
    Menon, Geetha
    Huang, Fleur
    Sloboda, Ron
    Pearcey, Robert
    Ghosh, Sunita
    BRACHYTHERAPY, 2014, 13 (06) : 572 - 578